Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | AADAC | P22760 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31122003 | 1.00 | ALDH1A1 (0.49) | ALDH1A1TDP1NPSR1TSHRSMN1; SMN2 | |
| SCHEMBL28300945 | 0.83 | ALDH1A1 (0.46) | ALDH1A1TDP1NPSR1TSHRSMN1; SMN2 | |
| SCHEMBL2524312 | 0.82 | TDP1 (0.58) | ALDH1A1TDP1TSHRSMN1; SMN2GPR35 | |
| SCHEMBL2431059 | 0.81 | TDP1 (0.64) | ALDH1A1TDP1NPSR1TSHRSMN1; SMN2 | |
| SCHEMBL30800293 | 0.81 | TDP1 (0.64) | ALDH1A1TDP1NPSR1TSHRSMN1; SMN2 | |
| SCHEMBL16852115 | 0.78 | ALDH1A1 (0.42) | ALDH1A1TDP1NPSR1SMN1; SMN2GPR35 | |
| SCHEMBL4725240 | 0.77 | TDP1 (0.48) | ALDH1A1TDP1TSHRSMN1; SMN2GPR35 | |
| SCHEMBL3038035 | 0.77 | RAB9A (0.48) | ALDH1A1TDP1NPSR1TSHRSMN1; SMN2 | |
| SCHEMBL30627320 | 0.76 | ALDH1A1 (0.50) | ALDH1A1TDP1NPSR1TSHRSMN1; SMN2 | |
| SCHEMBL1999849 | 0.76 | ALDH1A1 (0.50) | ALDH1A1TDP1NPSR1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223266-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-07-10 | — | — | US | disclosed |
| US-12129236-B2 | PARG inhibitory compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-10-29 | — | — | US | disclosed |
| US-20210380539-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| US-20210380539-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| EP-3907224-A1 | PARG INHIBITORY COMPOUNDS | Cancer Research Technology Limited (GB) | 2021-11-10 | — | — | EP | disclosed |
| EP-3907224-A1 | PARG INHIBITORY COMPOUNDS | Cancer Research Technology Limited (GB) | 2021-11-10 | — | — | EP | disclosed |
| EP-3233845-B1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECH LTD (GB) | 2021-07-21 | — | — | EP | disclosed |
| EP-3233845-B1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECH LTD (GB) | 2021-07-21 | — | — | EP | disclosed |
| US-10995073-B2 | PARG inhibitory compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-04 | — | — | US | disclosed |
| US-10995073-B2 | PARG inhibitory compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-04 | — | — | US | disclosed |
| WO-2020163236-A1 | TREATING LONG QT SYNDROME | THE GENERAL HOSPITAL CORPORATION (US) | 2020-08-13 | — | — | WO | disclosed |
| US-20200165208-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| US-20200165208-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| US-20180194738-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194738-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194738-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| EP-3233845-A1 | PARG INHIBITORY COMPOUNDS | Cancer Research Technology Limited (GB) | 2017-10-25 | — | — | EP | disclosed |
| CN-107295799-A | Parg inhibiting compounds | 癌症研究科技有限公司 | 2017-10-24 | — | — | CN | disclosed |
| WO-2016097749-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016097749-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380539-A1 | PARG INHIBITORY COMPOUNDS | PARP11, PARG, PARP16 | ALDH1A1 1411/4885TDP1 233/4885NPSR1 4088/4885 |
| US-20180194738-A1 | PARG INHIBITORY COMPOUNDS | PARG, PARP11, PARP16 | ALDH1A1 1483/4885TDP1 223/4885NPSR1 3993/4885 |
| US-10995073-B2 | PARG inhibitory compounds | PARG, PARP11, PARP16 | ALDH1A1 1483/4885TDP1 223/4885NPSR1 3993/4885 |
| US-12129236-B2 | PARG inhibitory compounds | PARP11, PARG, PARP16 | ALDH1A1 1411/4885TDP1 233/4885NPSR1 4088/4885 |
| US-20200165208-A1 | PARG INHIBITORY COMPOUNDS | PARG, PARP11, PARP16 | ALDH1A1 1483/4885TDP1 223/4885NPSR1 3993/4885 |
| US-20250223266-A1 | PARG INHIBITORY COMPOUNDS | PARG, PARP11, PARP16 | ALDH1A1 1483/4885TDP1 223/4885NPSR1 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.